0
POPSRozerem Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of insomnia agents selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA-A receptors.